Abcellera Biologics Inc
ABCL3.160USD
+0.380+13.67%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
944.88M시가총액
손실P/E TTM
자세한 내용은 Abcellera Biologics Inc 회사
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc 정보
종목 코드 ABCL
회사 이름Abcellera Biologics Inc
상장일Dec 11, 2020
CEOHansen (Carl L.G)
직원 수596
유형Ordinary Share
회계 연도 종료Dec 11
주소150 W 4Th Avenue
도시VANCOUVER
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Canada
우편 번호V5Y 1G6
전화16045599005
웹사이트https://www.abcellera.com/
종목 코드 ABCL
상장일Dec 11, 2020
CEOHansen (Carl L.G)
Abcellera Biologics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2024Q2
FY2023Q2
사업별USD
이름
수익
비율
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
주식 보유 통계
마지막 업데이트: Sun, Jan 25
마지막 업데이트: Sun, Jan 25
주주
주주 유형
주주
주주
비율
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
기타
61.11%
주주
주주
비율
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
기타
61.11%
주주 유형
주주
비율
Corporation
18.68%
Hedge Fund
16.25%
Investment Advisor
9.45%
Individual Investor
4.29%
Investment Advisor/Hedge Fund
3.93%
Research Firm
2.06%
Bank and Trust
0.69%
Pension Fund
0.29%
Sovereign Wealth Fund
0.21%
기타
44.14%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
315
112.27M
50.73%
-101.09K
2025Q3
340
112.51M
51.75%
-3.28M
2025Q2
368
115.12M
53.94%
-18.45M
2025Q1
420
133.63M
52.62%
-23.37M
2024Q4
441
121.95M
50.14%
+4.83M
2024Q3
440
121.95M
51.59%
-4.54M
2024Q2
439
127.07M
51.27%
-6.55M
2024Q1
432
134.44M
53.43%
-22.43M
2023Q4
425
138.44M
60.93%
-1.40M
2023Q3
426
134.18M
60.12%
-4.59M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Thermopylae Holdings Ltd
55.92M
18.68%
-225.00K
-0.40%
Dec 18, 2025
Baker Bros. Advisors LP
27.53M
9.2%
--
--
Sep 30, 2025
Capital World Investors
13.36M
4.46%
--
--
Sep 30, 2025
Two Sigma Investments, LP
9.99M
3.34%
+1.81M
+22.09%
Sep 30, 2025
Lecault (Veronique)
9.61M
3.21%
--
--
Apr 01, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Sep 30, 2025
Renaissance Technologies LLC
3.36M
1.12%
+53.30K
+1.61%
Sep 30, 2025
Tang Capital Management, LLC
2.60M
0.87%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.56M
0.85%
+1.79M
+234.13%
Sep 30, 2025
Millennium Management LLC
2.43M
0.81%
-967.85K
-28.49%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
iShares Genomics Immunology and Healthcare ETF
2.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Invesco Nasdaq Biotechnology ETF
0.16%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
더 보기
iShares Genomics Immunology and Healthcare ETF
비율2.64%
Virtus LifeSci Biotech Clinical Trials ETF
비율1.19%
ProShares Ultra Nasdaq Biotechnology
비율0.16%
Invesco Nasdaq Biotechnology ETF
비율0.16%
SPDR S&P International Small Cap ETF
비율0.12%
iShares Biotechnology ETF
비율0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
비율0.05%
Avantis US Small Cap Equity ETF
비율0.01%
SPDR Portfolio Developed World ex-US ETF
비율0.01%
Fidelity Nasdaq Composite Index ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
